Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug users

Addiction Biology

Volumn 21, Issue 4, 2016, Pages 885-894

  Ohana, David ^a,b   Maayan, Rachel ^c   Delayahu, Yael ^c,d   Roska, Paola ^e,f   Ponizovsky, Alexander M ^e   Weizman, Abraham ^c   Yadid, Gal ^b   Yechiam, Eldad ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d ABARBANEL MENTAL HEALTH CENTER   (Israel)

^e MINISTRY OF HEALTH   (Israel)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cortisol; decision making; DHEA; drug addiction; relapse

Indexed keywords

PLACEBO; PRASTERONE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; DETOXIFICATION; DRUG DEPENDENCE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL WELL BEING; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL; REHABILITATION CARE; TREATMENT OUTCOME;

EID: 84975072538     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12241     Document Type: Article

References (43)

1. Agay N, Yechiam E, Carmel Z, Levkovitz Y (2010) Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. Psychopharmacology (Berl) 210:511–519.
2. Alhaj HA, Massey AE, McAllister-Williams RH (2006) Effects of DHEA Administration on episodic memory, mood and cortisol in healthy young men: A double-blind, placebo-controlled study. Psychopharmacology 188:541–551.
3. Bardo MT, Klebaur JE, Valone JM, Deaton C (2001) Environmental enrichment decreases intravenous self-administration of amphetamine in female and male rats. Psychopharmacology (Berl) 155:278–284.
4. Bechara A, Damasio AR, Damasio H, Anderson SW (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50:7–15.
5. Buydens-Branchey L, Branchey M, Hudson J, Dorota MM (2002) Perturbations of plasma cortisol and DHEA-S following discontinuation of cocaine use in cocaine addicts. Psychoneuroendocrinology 27:83–97.
6. Clark N, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A, Ling W (2002) LAAM maintenance versus methadone maintenance for heroin dependence. Cochrane Database Syst Rev (2):CD002210.
7. Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD (2014) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol 19:562–574.
8. Diener E, Wirtz D, Tov W, Kim-Prieto C, Choi D, Oishi S, Biswas-Diener R (2009) New measures of well-being: flourishing and positive and negative feelings. Soc Indic Res 39:247–266.
9. Doron R, Fridman L, Gispan-Herman I, Maayan R, Weizman A, Yadid G (2006a) DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 31:2231–2236.
10. Doron R, Fridman L, Yadid G (2006b) Dopamine-2 receptors in the arcuate nucleus modulate cocaine-seeking behavior. Neuroreport 17:1633–1636.
11. Drake RE, Mercer-McFadden C, Mueser KT, McHugo QJ, Bond QR (1998) Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 24:589–608.
12. Dyer KR, White JM, Foster DJ, Bochner F, Menelaou A, Somogyi AA (2001) The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol 21:78–84.
13. Emrich HM, Vogt P, Hertz A (1982) Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci 398:108–112.
14. Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321–326.
15. Ert E, Yechiam E, Arshavsky O (2013) Smokers’ decision making: more than mere risk taking. PLOS ONE 8:e68064.
16. Feise RJ (2002) Do outcome measures require P-value adjustment? BMC Med Res Methodol 2:2–8.
17. Ferri M, Davoli M, Perucci CA (2006) Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness. J Subst Abuse Treat 30:63–72.
18. Ferri M, Davoli M, Perucci CA (2011) Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev (12):CD003410.
19. Fink LA, Bernstein D, Handelsman L, Foote J, Lovejoy M (1995) Initial reliability and validity of the childhood trauma interview: a new multidimensional measure of childhood interpersonal trauma. Am J Psychiatry 152:1329–1335.
20. Flood JF, Smith GE, Roberts E (1998) Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res 447:269–278.
21. Froeliger B, Modlin LA, Kozink RV, Wang L, McClernon FJ (2012) Smoking abstinence and depressive symptoms modulate the executive control system during emotional information processing. Addict Biol 17:668–679.
22. Lovallo WR (2007) Individual differences in response to stress and risk for addiction. In: al'Absi M, ed. Stress and Addiction: Biological and Psychological Mechanisms, pp. 227–248. New York: Elsevier.
23. Maayan R, Touati-Werner D, Shamir D, Yadid G, Friedman A, Eisner D, Weizman A, Herman I (2008) The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: a preliminary study. Eur Neuropsychopharmacology 18:406–413.
24. Malkesman O, Braw Y, Maayan R, Weizman A, Overstreet DH, Shabat-Simon M, Kesner Y, Touati-Werner D, Yadid G, Weller A (2006) Two different putative genetic animal models of childhood depression. Biol Psychiatry 59:17–23.
25. Mattick RP, Breen C, Kimber J, Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2):CD002207.
26. McLellan AT, Lewis DC, O'Brien CP, Kleber HD (2000) Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284:1689–1695.
27. Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367.
28. National Institute on Drug Abuse (NIDA) (2010) Drugs, Brains, and Behavior: The Science of Addiction. Available at: http://www.nida.nih.gov/scienceofaddiction/sciofaddiction.pdf. Accessed January 2015.
29. Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768–774.
30. Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 1141:105–130.
31. Solinas M, Chauvet C, Thiriet N, Rawas RE, Jaber M (2008) Reversal of cocaine addiction by environmental enrichment. Proc Natl Acad Sci U S A 105:17145–17150.
32. Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN (2004) Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 101:3202–3207.
33. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
34. Strous RD, Maayan R, Kotler M, Weizman A (2005) Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin Neuropharmacol 28:265–269.
35. Trainor BC (2011) Stress responses and the mesolimbic dopamine system: social contexts and sex differences. Horm Behav 60:457–469.
36. Wasserman DA, Weinstein MG, Havassy BE, Hall SM (1998) Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 52:183–192.
37. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 54:1063–1070.
38. Wechsler DA (1981) Wechsler Adult Intelligence Scale—Revised Manual. New York: Psychological Corporation.
39. Wilkins JN, Majewska MD, Van Gorp W, Li SH, Hinken C, Plotkin D, Setoda D (2005) DHEAS and POMS measures identify cocaine dependence treatment outcome. Psychoneuroendocrinology 30:18–28.
40. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E (1999) Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156:646–649.
41. Yadid G, Sudai E, Maayan R, Gispan I, Weizman A (2010) The role of dehydroepiandrosterone (DHEA) in drug-seeking behavior. Neurosci Biobehav Rev 35:303–314.
42. Yadid G, Redlus L, Barnea R, Doron R (2012) Modulation of mood states as a major factor in relapse to substance use. Front Mol Neurosci 5:1–5.
43. Zhang J, Quan H, Ng J, Stepanavage ME (1997) Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 18:204–221.